|
| U.S. Brand
Names |
|
| YF-VAX® |

|
|
| Generic
Available |
|
|
No |

|
|
| Pharmacological Index |
|
|
Vaccine |

|
|
| Use |
|
|
Induction of active immunity against yellow fever virus, primarily among
persons traveling or living in areas where yellow fever infection exists. (Some
countries require a valid international Certification of Vaccination showing
receipt of vaccine; if a pregnant woman is to be vaccinated only to satisfy an
international requirement, efforts should be made to obtain a waiver letter.)
The WHO requires revaccination every 10 years to maintain traveler's vaccination
certificate. |

|
|
| Pregnancy Risk
Factor |
|
|
D |

|
|
| Contraindications |
|
|
Sensitivity to egg or chick embryo protein; pregnant women, children <6
months of age unless in high risk area |

|
|
| Warnings/Precautions |
|
|
Do not use in immunodeficient persons or patients receiving
immunosuppressants (eg, steroids, radiation); have epinephrine available in
persons with previous history of egg allergy if the vaccine must be used. Avoid
use in infants <6 months and pregnant women unless travel to high-risk areas
are unavoidable; avoid use in infants <4 months of age. |

|
|
| Adverse
Reactions |
|
|
All serious adverse reactions must be reported to the U.S. Department of
Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS)
1-800-822-7967.
1% to 10%:
Central nervous system: Headache (2% to 5%)
Neuromuscular & skeletal: Myalgia (2% to 5%)
<1%: Encephalitis in very young infants (rare), anaphylaxis
|

|
|
| Drug
Interactions |
|
|
Administer yellow fever vaccine at least 1 month apart from other live virus
vaccines; defer vaccination for 3 weeks following immune globulin; concurrent
cholera and yellow fever and concurrent hepatitis B vaccine and yellow fever
vaccines may decrease immune response; separate vaccinations by 1 month, if
possible; defer vaccination for 8 weeks following blood or plasma
transfusion |

|
|
| Stability |
|
|
Yellow fever vaccine is shipped with dry ice; do not use vaccine unless
shipping case contains some dry ice on arrival; maintain vaccine continuously at
a temperature between 0°C to 5°C
(32°F to 41°F) |

|
|
| Usual Dosage |
|
|
One dose (0.5 mL) S.C. 10 days to 10 years before travel, booster every 10
years; see Warnings/Precautions |

|
|
| Patient
Information |
|
|
Immunity develops by the tenth day and WHO requires revaccination
every 10 years to maintain travelers' vaccination
certificates |

|
|
| Nursing
Implications |
|
|
Sterilize and discard all unused rehydrated vaccine and containers after 1
hour; avoid vigorous shaking |

|
|
| Dosage Forms |
|
|
Injection: Not less than 5.04 Log10 Plaque Forming Units (PFU) per
0.5 mL |

|
|
Copyright © 2007 Drugs Area
|